Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Vaccine Safety


Section Navigation
			
			CDC Home








Pneumococcal Vaccines						Print
																Related Pages
										On This Page
			Pneumococcal Disease and How to Protect Against ItPneumococcal Vaccine Side EffectsAvailable Pneumococcal VaccinesHow CDC Monitors Vaccine SafetyA Closer Look at the Safety DataMore ResourcesRelated Scientific ArticlesRelated Links
		
Safety InformationPneumococcal Disease and How to Protect Against It
**Pneumococcal disease** is an infection caused by *Streptococcus pneumoniae* bacteria, sometimes referred to as pneumococcus. Pneumococcus can cause many types of illnesses, including ear and sinus infections, pneumonia, and bloodstream infections. You can protect against pneumococcal disease with safe, effective vaccination.Child and Adult Immunization Schedules
Get CDC’s official recommended immunization schedules for children, adolescents, and adults.Pneumococcal Vaccine Side Effects
Pneumococcal vaccines are very safe and effective at preventing pneumococcal disease. Vaccines, like any medicine, can have side effects. The most common side effects from pneumococcal vaccines are mild and last for 1 or 2 days.Common Side Effects of Pneumococcal VaccineFeeling drowsy
Loss of appetite
Sore or swollen arm from the shot
Fever
HeadacheVery rarely, severe (anaphylactic) allergic reactions may occur after vaccination.Top of PageAvailable Pneumococcal Vaccines
There are four pneumococcal vaccines approved for use in the United States. Learn more about who should get which vaccine(s).
Pneumococcal conjugate vaccines (PCV13, PCV15, PCV20)
**Prevnar13 (PCV13)** [PDF – 43 pages]: The Food and Drug Administration (FDA) approved this vaccine in 2010 for use in children and in 2011 for use in adults. PCV13 replaced a previous pneumococcal vaccine, PCV7. PCV13 helps protect against 13 types of pneumococcal bacteria that cause the most severe illness among children and adults.
**Vaxneuvance (PCV15)** [PDF – 24 pages]: FDA approved this vaccine in 2021 for use in adults and in 2022 for use in children. PCV15 helps protect against 15 types of pneumococcal bacteria that commonly cause severe illness among adults.
**Prevnar20 (PCV20)** [PDF – 33 pages]: FDA approved this vaccine in 2023 for use in individuals ages 6 weeks and older. PCV20 helps protect against 20 types of pneumococcal bacteria that commonly cause severe illness among adults.Pneumococcal polysaccharide vaccine (PPSV23)
**Pneumovax 23 (PPSV23)** [PDF – 8 pages]: FDA approved this vaccine in 1983. It helps protect against serious infections caused by 23 types of pneumococcal bacteria.Top of PageHow CDC Monitors Vaccine Safety
CDC and FDA monitor the safety of vaccines after they are approved or authorized. If a problem is found with a vaccine, CDC and FDA will inform health officials, health care providers, and the public.
CDC uses 3 systems to monitor vaccine safety:
The Vaccine Adverse Event Reporting System (VAERS): an early warning system, co-managed by CDC and FDA, to monitor for potential vaccine safety problems. Anyone can report possible vaccine side effects to VAERS.
The Vaccine Safety Datalink (VSD): a collaboration between CDC and 13 healthcare organizations that conducts vaccine safety monitoring and research.
The Clinical Immunization Safety Assessment (CISA) Project: a partnership between CDC and several medical research centers that provides expert consultation and conducts clinical research on vaccine-associated health risks.
Top of PageA Closer Look at the Safety Data
A 2004 study found most VAERS reports in the first 2 years after licensure of 7-valent pneumococcal conjugate vaccine (PCV7) were minor known side effects.
Two large 2013 studies (Jackson et al; Jackson et al) conducted in the United States and Europe in adults ages 50 years and older compared PCV13 with PPSV23. Common adverse events reported with PCV13 were pain, redness, and swelling at the injection site; limited movement of the injected arm; tiredness; headache; chills; decreased appetite; generalized muscle pain; and joint pain.  Similar reactions were observed in adults who received PPSV23.
A 2012 study showed that children who received both 2010-2011 trivalent influenza (flu) vaccine and PCV13 at the same doctor visit had a higher risk of fever-related seizures (febrile seizures).Top of PageMore Resources
Pneumococcal Vaccine Information Statement
Pneumococcal Vaccine: Who Should Not Be Vaccinated
Pneumococcal Vaccination: Who Needs It?
U.S. Vaccine Abbreviations [PDF – 5 pages]Top of PageRelated Scientific Articles
Centers for Disease Control and Prevention. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. *MMWR*. 2012 Jun 1;61(21):394-5.
Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: A RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. *Neth J Med*. 2008;66:378–83.
Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. *Vaccine.* 2013;31:3577–84.
Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Vaccine.* 2013;31:3585–93.
Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Talbot HK, Poehling KA, Pilishvili T. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. *MMWR*. 2022;71(4);109–117.
Kobayashi M, Farrar JL, Gierke R, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Poehling KA, Cohen AL. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. *MMWR*. 2022;71(37);1174–1181.
Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of PCV-13 and PPSV-23 vaccine among adults aged 65 and older: Recommendations of the ACIP. *MMWR*. 2014;63(37);822-825.
Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM; VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. *Vaccine*. 2012 Mar 2;30(11):2024-31.
Wise RP, Iskander J, Pratt RD, Campbell S, Ball R, et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. *JAMA*. 2004 Oct 13;292(14):1702-10.Top of PageRelated LinksFacts About Pneumococcal Disease for Adults
Pneumococcal Vaccination Recommendations By Age And Risk Factor [PDF -1 page]
COPD, Asthma, and Adult Vaccines Fact Sheet [PDF – 1 page]
Pneumonia Can Be Prevented—Vaccines Can HelpTop of Page
							
					
							Last Reviewed:  May 12, 2023						Source: 	Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP)
					Facebook
        Twitter
        LinkedIn
        Syndicate homeVaccine Safety
Safety Information by Vaccineplus icon
Chickenpox (Varicella) Vaccines
COVID-19 Vaccines
Diphtheria, Tetanus, and Pertussis Vaccines
Haemophilus influenzae type b (Hib) Vaccines
Hepatitis A Vaccines
Hepatitis B Vaccines
Human Papillomavirus (HPV) Vaccineplus icon
Questions about HPV Vaccine Safety
Influenza (Flu) Vaccines
Measles, Mumps, Rubella (MMR) Vaccinesplus icon
MMR Safety Studies
Measles, Mumps, Rubella, Varicella (MMRV) Vaccinesplus icon
VSD MMRV Safety Study
MMRV Safety Studies
MMRV and Febrile Seizures
Meningococcal Vaccines
Mpox Vaccines
Pneumococcal Vaccines
Polio Vaccine
Respiratory Syncytial Virus (RSV) Vaccine
Rotavirus Vaccine
Shingles (Herpes Zoster) Vaccines
Smallpox Vaccines
Questions and Concernsplus icon
Adjuvants
Autismplus icon
CDC Statement: 2004 Pediatrics Paper on MMR and Autism
Fainting after Vaccination
Febrile Seizures
Guillain-Barre Syndrome
Multiple Vaccinations at Once
Sudden Infant Death Syndrome (SIDS)
Thimerosalplus icon
CDC Study (2010 ) on Thimerosal and Risk of Autism
Thimerosal FAQs
Related Scientific Articles
Infant and Environmental Exposures to Thimerosal 2007 Study
Timeline: Thimerosal in Vaccines
Vaccines During Pregnancy FAQs
FAQs about Vaccine Recalls
Historical Vaccine Safety Concernsplus icon
GBS and Menactra Vaccine FAQs
Gardasil Vaccine Recall (2013) FAQs
Hep B and Multiple Sclerosis FAQs
Hib Vaccine Recall (2007) Summary
Narcolepsy Following Pandemrix Influenza Vaccination in Europe
Information for Healthcare Providersplus icon
Talking to Patients About Vaccine Safety
Reporting Adverse Events
Resources for Healthcare Providers
Information for Parents and Caregiversplus icon
Vaccine Safety FAQs
Researchplus icon
Publications
Partner Reports on Vaccine Safety
ISO Scientific Agenda
Ensuring Safetyplus icon
Overview, History, and How It Works
Side Effects and Adverse Events
Vaccine Safety Monitoringplus icon
Vaccine Adverse Event Reporting System (VAERS)
CISAplus icon
CISA Resources for Healthcare Professionals
Evaluation
Clinical Research Studies
Historical Background 2001-12
Publications
Technical Reports
Vaccine Safety Datalink (VSD)plus icon
Accessing Data from Vaccine Safety Datalink
Data Sharing Guidelines
Vaccine Safety Datalink Publications
V-safe
V-safe Publications
Emergency Preparedness
Vaccine Safety Partners
About ISO To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue